Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.33
-0.31 (-1.37%)
At close: Jun 18, 2026, 4:00 PM EDT
22.33
0.00 (0.01%)
After-hours: Jun 18, 2026, 4:24 PM EDT

Pacira BioSciences Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Buy" and an average price target of $29.67. The average 1-year stock price forecast is 32.87% higher than the current stock price, while the lowest is $23 (+3.00%) and the highest is $38 (+70.17%).

Price Target: $29.67 (+32.87%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$23$29.67$28.5$38
Change+3.00%+32.87%+27.63%+70.17%
* Price targets were last updated on May 14, 2026.

Analyst Ratings

The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy333333
Buy111111
Hold222222
Sell111111
Strong Sell000000
Total777777

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Barclays
Barclays
Hold
Maintains
$25
HoldMaintains$25+11.96%May 14, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$38
BuyReiterates$38+70.17%May 4, 2026
Truist Financial
Truist Financial
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 1, 2026
RBC Capital
RBC Capital
Hold
Maintains
$22$24
HoldMaintains$22$24+7.48%May 1, 2026
Needham
Needham
Buy
Maintains
$30$32
BuyMaintains$30$32+43.30%May 1, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
767.79M
from 726.41M
Increased by 5.70%
Revenue Next Year
831.29M
from 767.79M
Increased by 8.27%
EPS This Year
2.88
from 2.65
Increased by 8.57%
EPS Next Year
3.65
from 2.88
Increased by 26.79%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
541.53M666.82M674.98M700.97M726.41M767.79M
Revenue Growth
26.04%23.14%1.22%3.85%3.63%5.70%
Gross Profit
401.28M467.53M490.31M530.54M576.66M606.81M
Gross Margin
74.10%70.11%72.64%75.69%79.39%79.03%
Operating Income
89.92M70.93M87.32M97.57M33.30M158.41M
Net Income
41.98M15.91M41.96M-99.56M7.03M36.63M
EPS
----2.652.88
EPS Growth
-----17.19%8.57%
Forward PE
15.4311.6410.237.107.537.76
Free Cash Flow
49.79M92.00M107.15M163.38M108.56M157.00M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High769.0M
Avg767.8M
Low766.5M

Revenue Growth

Revenue Growth202620272028
High
5.9%
Avg
5.7%
Low
5.5%

EPS Forecast

EPS202620272028
High2.98
Avg2.88
Low2.74

EPS Growth

EPS Growth202620272028
High
12.5%
Avg
8.6%
Low
3.3%